Aslan Pharmaceuticals Pte. Ltd., of Singapore, said its IND to run a phase II trial of ASLAN-003 in patients with acute myeloid leukemia was approved by Singapore's Health Sciences Authority. The primary outcome of the dose-optimization study is overall complete remission rate.